KHIRONMED

We, for you!


As part of KHIRON Life Sciences Corporation,
we want to promote cannabinoid-based medicine in
UK.

Doctors Login

KHIRONMED

We, for you!

As part of KHIRON Life Sciences Corporation,
we want to promote cannabinoid-based medicine in
UK.

Doctors Login

Welcome to Khiron

KhironMed is the medical division of KHIRON Life Sciences Corporation, a leading, vertically integrated, international medical cannabis company with core operations in Latin America and Europe. We strongly believe in the role of medical cannabis to improve health-related quality of life of people. This is why our priority is to support patients through:

of high-quality pharmaceutical products.

of continuing medical cannabis education programs for healthcare professionals.

We stand for...

tabs-image

Transparency

We stand for full transparency within our company and towards doctors, pharmacists and patients.

Learn more
tabs-image

Quality

We are constantly working on the further development of our high-quality (GMP-certified) cannabinoid-based pharmaceutical products.

Learn more
tabs-image

Reliability

Disruptions in product availability are to the expense of patients and prescribing doctors. We stand for reliability: a central value that determines our internal and external appearance.

Learn more
tabs-image

Integrity

We transfer our values lived in Latin America to Great Britain and use our clinical data from thousands of patients.

Learn more
tabs-image

Equality

We are consistently committed to equality - both inside and outside our company.

Learn more

Project Twenty21

ds_logo

Khiron is the first and only Latin-American provider in Project Twenty21 in the UK.

Project Twenty21 is the first and largest medical cannabis patient registry in Europe

Project Twenty21 aims to enroll 20.000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis.

 

Project Twenty21 is enrolling patients who have been diagnosed with one of the following conditions:

 

Chronic Pain, Anxiety Disorder, Multiple Sclerosis, Tourette Syndrome, Post-Traumatic Stress Disorder (PTSD), Substance use disorder (as a harm reduction strategy)

[rev_slider slidertitle=”Medicare Research1″ alias=”medicare-research1″]

What's new?

Our team of experts regularly informs you about
changes in the industry.

June 8, 2021

THE CBD-ILEMMA

The approval of epidyolex for the treatment of refractory pediatric epilepsy is providing an increasing body ...
Read More
May 7, 2021

A tale of two (cannabis) registries

A tale of two (cannabis) registries In the last month, we have seen ...
Read More

Our partners

Our partners in UK

MCCS_LOGO_Symbol
ds_logo
MCCS_LOGO_Symbol
ds_logo
CIC member[4733]